AstraZeneca goes to battle with GSK with nod for Nucala challenger Fasenra
admin 15th November 2017 Uncategorised 0AstraZeneca is about to find out whether its third-to-market respiratory biologic can stand out from the crowd—and a lower price might just do it. Fasenra, known in the clinic as benralizumab, won FDA approval for a severe type of asthma, and AZ is undercutting its two chief rivals.
More: AstraZeneca goes to battle with GSK with nod for Nucala challenger Fasenra
Source: fierce